Unnati Pharmaceuticals Private Limited, a active private limited company, was established on 24 June 2003 in Mumbai, Maharashtra, India. Engaging in medicinal chemical & botanical products within the manufacturing sector, it holds CIN: U24231MH2003PTC428884. Registered under ROC Roc Mumbai. it is unlisted. It has an authorized capital of ₹1.05 M and a paid-up capital of ₹0.90 M.
It upholds a compliant status. Its leadership includes Naishil Hetal Mehta (Director), Hetal Bhupatrai Mehta (Director). Past directors included Kaushik Kantilal Parekh, Kiran Chandrakant Sanghavi, Naishil Hetal Mehta. It holds ₹12.88 Cr open charges and no settled loans. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at Unit No 301/401 Sai Chambers Chs Ltd Road No 3, Near Santacruz Bus Depot, Mumbai, Maharashtra, 400055.
U24231MH2003PTC428884
428884
24 June 2003
₹1.05 M
₹0.90 M
Roc Mumbai
Unlisted
Active
Explore comprehensive insights into Unnati Pharmaceuticals Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Naishil Hetal Mehta | Director | 21 Dec 2016 | Current |
| Hetal Bhupatrai Mehta | Director | 30 Jun 2010 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 31 May 2009 | Past |
| Pramod Abcsdd | Director | 30 Nov 2011 | Past |
| Pramod Abcsdd | Additional Director | 30 Sep 2017 | Past |
| Pramod Abcsdd | Additional Director | 21 Dec 2016 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Unnati Pharmacuticals Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 2.93% decrease. The company also saw a substantial fall in profitability, with a 46.7% decrease in profit. The company's net worth moved up by a moderate rise of 7.9%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Unnati Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹128,834,500.00
₹0
| Date | Lender | Amount | Status |
|---|---|---|---|
| 04 Mar 2022 | Hdfc Bank Limited | ₹1.33 M | Open |
| 12 Mar 2018 | Hdfc Bank Limited | ₹5.00 Cr | Open |
| 28 Feb 2008 | Hdfc Bank Limited | ₹7.75 Cr | Open |
Explore comprehensive loan charge details -
Unlock and access historical data on people associated with Unnati Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Unnati Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Unnati Pharmaceuticals's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
A charge with Hdfc Bank Limited of Rs. 77.50 M registered on 28 Feb 2008 with Charge ID 10114657 was modified on 21 Mar 2025. was recorded as a recent event.
Progress on Unnati Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was documented.
The activity Unnati Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Mumbai. was completed.
A charge with Hdfc Bank Limited amounted to Rs. 1.33 M with Charge ID 100558502 was registered on 04 Mar 2022. was recorded as a recent event.
A charge with Hdfc Bank Limited amounted to Rs. 50.00 M with Charge ID 100193433 was registered on 12 Mar 2018. was recorded as a recent event.
Progress on Naishil Hetal Mehta was appointed as a Director was appointed as a Director on 21 Dec 2016 & has been associated with this company since 8 years 11 months . was documented.
The CIN of Unnati Pharmaceuticals Private Limited is U24231MH2003PTC428884.
Unnati Pharmaceuticals Private Limited is headquartered at Unit No 301/401 Sai Chambers Chs Ltd Road No 3, Near Santacruz Bus Depot, Mumbai, Maharashtra, 400055.
Unnati Pharmaceuticals Private Limited was incorporated on 24 June 2003.
The current directors of Unnati Pharmaceuticals Private Limited are
The primary industry of Unnati Pharmaceuticals Private Limited is Manufacturing.
Unnati Pharmaceuticals Private Limited is unlisted.
The authorized capital of Unnati Pharmaceuticals Private Limited is ₹1.05 M, and the paid-up capital is ₹0.90 M.
The compliance status of Unnati Pharmaceuticals Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX